Нейтрофилы и факторы их активации у больных идиопатическим фиброзирующим альвеолитом
Диссертация
В основном, изучение патогенеза ИФА сосредоточено на оценке клинической картины заболевания, уточнении критериев диагностики и разработке адекватной терапии. Предполагается, что в основе патогенеза ИФА лежат иммунопатологические реакции (Hogg J.C., 1999; Molina V., Shoenfeld Y., 2002; Davies HR., Richeldi L., 2003). В связи с возрастающей распространенностью ИФА, неоднозначностью сведений… Читать ещё >
Список литературы
- Авдеева О.Е., Авдеев С. Н., Чучалин А. Г. Идиопатический фиброзирующий альвеолит. // Русский медицинский журнал, 1998 -Т.6. № 4 — С. 228 — 234.
- Волчков В.А. Краткое практическое руководство по биометрии для врачей. СПб, 1998. — 63 с.
- Герасин В.А., Паламарчук Г. Ф., Журавлев А. В. Диагностический бронхоальвеолярный лаваж в оценке эффективности лечения идиопатического фиброзирующего альвеолита // Терапевтический архив. 1988. — № 12. — 84 с.
- Данилов Л.Н., Лебедева Е. С., Колесов В. А., Двораковская .В., Сесь Т. П. Моделирование токсического фиброзирующего альвеолита. В сб. научн. трудов «Актуальные проблемы пульмонологии».- Л., 1991.- С. 45−48.
- Двораковская И.В., Илькович М. М. Идиопатический фиброзирующий альвеолит (болезнь Хаммена-Рича). В кн.: «Фиброзирующие альвеолиты». Л.: Медицина, 1986.- С. 6−100.
- Илькович М.М. Заболевания органов дыхания //Библиотека врача общей практики, СПб, «Нордмед Издат», 1998.- Т 2. — 452 с.
- Илькович М.М., Новикова Л. Н. Интерстициальные заболевания легких // Руководство для врачей, под редакцией А. Н. Кокосова. -СПб.: «Нордмед-Издат», 2005.- С. 30 182.
- Кетлинский С.А., Калинина Н. М. Иммунология для врача. СПб, 1998.- 156 с.
- Кетлинский С.А., Калинина Н. М. Цитокины мононуклеарных фагоцитов в регуляции реакции клеточного воспаления и иммунитета. Иммунология. — 1995. — № 1. — С. 30 — 44.
- П.Кетлинский С. А., Симбирцев А. С., Воробьев А. А. Эндогенные иммуномодуляторы. СПб.: Гиппократ, 1992.
- Клемент Р.Ф., Лаврушин А. А., Котегов Ю. М., Тер-Погосян П.А. Инструкция по применению формул и таблиц должных величин основных спирографических показателей // Л.: Медицина, 1986. -С.79. ¦
- Коган Е.А. Фиброзирующий альвеолит современные аспекты. // Архив патол. — 1995. — № 4. — С. 5- 11.
- Кузнецова В.К., Садовская М. П., Буланина Е. М. Хронический бронхит в свете функционально-диагностического исследования // Современные проблемы клинической физиологии дыхания / Под ред. Р. Ф. Клемента и В. К. Кузнецовой. Л.: Медицина, 1987. — С.71−89.
- Маянский Д.Н. Хроническое воспаление. М.: Медицина, 1991, -272 с.
- Механизмы иммунопатологии. Под ред. С. Коена, А. П. Уорда, Р.Т. Мак-Класки. М., Медицина. 1983. 398 с.
- Немцов В.И., Федосеев Г. Б. Клеточные и медиаторные механизмы патогенеза воспаления бронхов и легких. В кн.: «Механизмы воспаления бронхов и легких и противовоспалительная терапия». -СПб.: «Нордмед Издат», 1998. — С. 308 — 335, — С. 363 — 386.
- Пауков B.C., Серов В. В. Сущность воспаления, его место в биологии и медицине / В кн. «Воспаление». М.: 1995, С. 30 — 38.
- Полосухин В.В. Альвелярные макрофаги: структурно -функциональная гетерогенность и хроническое воспаление легких. // Успехи современной биологии. 1995, — С. 740 — 758.
- Попова Е.Н., Козловская JI.B., Фомин В. В., Корнев Б. М. Идиопатический фиброзирующий альвеолит и хронические идиопатические интерстициальные пневмонии: современные аспекты диагностики и лечения. // Consilium medicum. 2005, — Т.7 — № 4 -154с.
- Путов Н.В., Илькович М. М. Фиброзирующие альвеолиты. JL: Медицина, 1986.- 168 с.
- Ройт А. Основы иммунологии. М.: Мир, 1991, 328 с.
- Сесь Т.П., Колодкина JI.H., Котенко Т. В. Характеристика аутоиммунного компонента хронического воспалительного процесса при идиопатическом фиброзирующем альвеолите. // Медицинская иммунология. 2000. — № 3. — С. 291 — 298.
- Тареев Е.М. Редкие диагнозы и редкие болезни. Терапевтический архив, 1974, N2, С. 3.
- Тюрин И.Е. Интерстициальные заболевания легких. В кн.: «Компьютерная томография органов грудной полости». СПб.: ЭЛБИ-СПб.- 2003.- С. 326−331.
- Фрейдлин И.С. Иммунология для врачей. СПб., 1999.
- Фрейдлин И.С., Тотолян А. А. Иммунологические механизмы воспаления бронхов и легких. В кн.: «Механизмы воспаления бронхов и легких и противовоспалительная терапия», под ред. проф. Г. Б. Федосеева. СПб.: «Нордмед — Издат», 1998. — С. 194 — 298.
- Шмелев Е.И. Идиопатический фиброзирующий альвеолит.// АтмосферА. Пульмонология и аллергология.- 2004. № 1.- С. 3−8.
- Ярилин А.А. // Система цитокинов при иммунопатологии. Сб. труд. 1 Нац. Конф. РААКИ. М., 1997. С. 161 — 168.
- Ярилин А.А. Основы иммунологии. М.: Медицина, 1999. — С. 230 -278.
- Acharya P. S, Zisman D.A. Antifibrotic therapy for idiopathic pulmonary fibrosis.// Clinical Pulmonary Medicine 2001 Vol.8, № 6, p. 327−334.
- American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. ATS and ERS. //Am. J. Respir. Crit. Care Med. -2000. Vol.16. — P. 646−664.
- Ando M, Miyazaki E, Fukami T, Kumamoto T, Tsuda T. Interleukin-4-producing cells in idiopathic pulmonary fibrosis: an immunohistochemical study. Respirology. 1999−4(4):383−91.
- Antoniou K.M., Ferdoutsis E., Bouros D. Interferons and their application in the diseases of the lung. Chest 2003- 123(1):209−16.
- Baecher-Allan CM, Barth RK. PCR analysis of cytokine induction profiles associated with mouse strain variation in susceptibility to pulmonary fibrosis. Reg Immunol. 1993−5(3−4):207−17.
- Baumgartner K.B., Samet J.M., Stidley C.A., Colbi T.V., Waldron J.A. Cigarette smoqing: risk factor for idiopathic pulmonary fibrosis.// Am. J. Respir. Crit. Care Med. 1997.- Vol.155. — P. 242−248.
- Beeh K.M., Beier J., Kornmann O., Buhl R. Neutrophilic inflammation in induced sputum of patients with idiopathic pulmonary fibrosis. Sarcoidosis Vase. Diffuse Lung Dis. 2003- 20(2): 138−43.
- Bianchi M., Fantuzzi G., Bertini R., Perin L., Salmona M., Ghezzi P. The pneumotoxicant paraquat induces IL-8 mRNA in human mononuclear cells and pulmonary epithelial cells. Cytokine. 1993- 5(5):525−30
- Bianchi M., Fantuzzi G., Bertini R., Perin L., Salmona M., Ghezzi P. The pneumotoxicant paraquat induces IL-8 mRNA in human mononuclear102cells and pulmonary epithelial cells. Cytokine. 1993- 5(5):525−30.
- Bienkowski R.S., Gotkin M.G. Control of collagen deposition in mammalian lung. Proc Soc Exp Biol Med. 1995- 209(2): 118−40.
- Bjoraker J.A., Ryu J.H., Edwin M.K. Prognostic significance of histopathologic: subsets in idiopathic pulmonary fibrosis.//Am. J Respir. Crit Care Med.- 1998.-Vol.157.-P. 199−233.
- Carre P., Leophonte P. Cytokines and pulmonary fibroses. Rev Mai Respir. 1993- 10(3): 193−207.
- Carrington C.B., Gaensler E.A., Coutu R.E., Fitzerald M.X., Gupta R.G. Natural hystory and treated course of usual and desquamative interstitial pneumonia. N. Engl. J. Med. 1978- 298:801−9
- Carvalho C.R., Kairalla R.A., Schettino G.P. Acute respiratory failure after interferon-gamma therapy in IPF. Am J. Respir. Cri. t Care Med. 2004- 169(4):543−4.
- Chan-Yeung M, Muller NL. Cryptogenic fibrosing alveolitis. Lancet 1997−350:651−6.
- Chen W., Li Z., Hou X. Level of NCF and TNF-alpha in the BALF of ILD patients and their clinical significance. Zhonghua Jie He He Hu Xi Za Zhi. 1998- 21(5):297−9.
- Cherniack RM, Colby TV, Flint A, et al. Correlation of structure and function in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1995- 151:1180−8.
- Cherniack RM, Crystal RG, Kalica AR. Current concepts in idiopathic pulmonary fibrosis: A road map for the future. Am Rev Respir Dis 1991- 43:680−6.
- Coker R.K., Laurent G.J. Anticytokine approaches in pulmonary fibrosis: bringing factors into focus. Thorax. 1997- 52(3):294−6.
- Coker R.K., Laurent G.J. Pulmonary fibrosis: cytokines in the balance. Eur. Respir. J. 1998- 11(6):1218−21
- Colby V. Update on idiopathic interstitial pneumonias. // ATS Postgraduate Course. Toronto May 6, 2000.
- Cook D.N., Brass D.M., Schwartz D.A. A matrix for new ideas in pulmonary fibrosis. Am J. Respir. Cell Mol. Biol. 2002- 27(2): 122−4.
- Corrin B. Pathology of interstitial lung disease. Semin Resp Crit Care Med 1994−15:61−76
- Coultas D.V., Zumvalt R.E., Black W.S., Sobonia R.E. The Epidemiologia of interstitial lung disease.// Am. J. Respir. Crit. Care Med. 1994.- Vol. 150. — P. 967−972.
- Crystal R.G., Bitterman P.B., Rennard S.I., Hance A.J., Keorgh B.A. Interstitiallung diseases of unknown cause: disorders characterized by chronic inflammation of the lower respiratory tract. \ N. Engl. J. Med.-1984.- Vol.310. -. P. 154−166, 235−244.
- Crystal R.G., Fulmer J.D., Roberts W.C., et al. Idiopathic pulmonary fibrosis: Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann. Intern. Med. 1976- 85:769−88.
- Crystal R.G., Gadek J.E., Ferrans V J., Fulmer J.D., Line B.R., Hunninghake G.W. Interstitial lung disease: current concepts of pathogenesis, staging and therapy. Am J. Med. 1981- 70:542−68.
- Dallergi F., Ottonello L Tissue injri in neutrophil inflammation. Inflammation Res. 1997 V.46 P. 382−391.
- Dauber J.H., Gibson K.F., Kaminski N. Interferon-gamma lb in idiopathic pulmonary fibrosis: what we know and what must we learn. Am J. Respir. Cri. t Care Med. 2004- 170(2): 107−8.
- Davies H.R., Richeldi L., Walters E.H. Immunomodulatory agents for idiopathic pulmonary fibrosis. Cochrane Database Syst. Rev. 2003- (3):CD003134.
- Dubaybo B.A. Role of tumor necrosis factor-alpha in regulating fibrotic lung repair. Res. Commun. Mo. l Pathol. Pharmacol. 1998- 101(l):69−83
- Egan J.J., Woodcock A.A., Stewart J.P. Viruses and idiopatic pulmonary fibrosis.//Eur. Respir. J. 1997. Vol.10.- P. 1433−1437.
- Egan JJ, Woodcock AA. Does the treatment of cryptogenic fibrosing alveolitis influence prognosis? Respir Med 1996- 90:127−30.
- Elias J.A., Freundlich В., Kern J.A., Rosenbloom J. Cytokine networks in the regulation of inflammation and fibrosis in the lung. Chest. 1990- 97(6): 1439−45.
- Emad A. Bronchoalveolar lavage: A useful method for diagnosis of some pulmonary disorders. Respir Care 1997- 42:765−90.
- Entzian P., Schlaak M., Seitzer U., Bufe A., Acil Y., Zabel P. Antiinflammatory and antifibrotic properties of colchicine: implications for idiopathic pulmonary fibrosis. Lung. 1997- 175(1):41−51.
- Finkelstein J.N., Johnston C., Barrett Т., Oberdorster G. Particulate-cell interactions and pulmonary cytokine expression. Environ Health Perspect. 1997- 105 5:1179−82.
- Freudenberger Т., Raghu J. Idiopathic pulmonary fibrosis: an evolving approach to diagnosis and treatment. In: Europen Respiratory Monograph «Interstitial Lung Diseases».- 2000.- Vol.5. P. 79−96.
- Fries KM, Felch ME, Phipps RP. Interleukin-6 is an autocrine growth factor for murine lung fibroblast subsets. Am J Respir Cell Mol Biol. 1994 Nov-ll (5):552−60.
- Furuie H., Yamasaki H., Suga M., Ando M. Altered accessory cell function of alveolar macrophages: a possible mechanism for induction of Th2 secretory profile in idiopathic pulmonary fibrosis. Eur. Respir. J. 1997- 10(4):787−94.
- Gu L., Xu W.B., Liu H.R., Guo Z.J., Xu X.X., Zhu Y.J. Different cytokine profiles in usual interstitial pneumonia and nonspecific interstitial pneumonia. Zhonghua Jie He He Hu Xi Za Zhi. 2003- 26(6):350−3.
- Guo Z., Cao В., Zhu Y., Xu W. The potential role of cytokines expression in idiopathic pulmonary fibrosis. Zhonghua Jie He He Hu Xi Za Zhi. 1999- 22(l):33−6.
- Hagimoto N., Kuwano K., Kawasaki M., Yoshimi M., Kaneko Y. Induction of interleukin-8 secretion and apoptosis in bronchiolar epithelial cells by Fas ligation. Am J. Respir Cell Mol Biol. 1999- 21(3):436−45.
- Hallahan D.E., Geng L., Shyr Y. Effects of intercellular adhesionmolecule 1 (ICAM-1) null mutation on radiation-induced pulmonary fibrosis and respiratory insufficiency in mice. J. Natl. Cancer Inst. 2002- 94(10):733−41.
- Hamman L., Rich A.R. Acute diffuse interstitial fibrosis of the lungs. //Bull. John Hopkins Hospital. 1944.-Vol.74. — P. 177−204.
- Hamman L., Rich A.R. Fulminating diffuse interstitial fibrosis of the lungs. //Trans Am. Clin. Climatol. Assoc. 1935. — Vol.51. — P. 154−163.
- Hanaoka M., Kubo K., Yamaguchi S., Hayano Т., Koizumi T. Two patients with idiopathic pulmonary fibrosis and monoclonal gammopathy. Nihon Kyobu Shikkan Gakkai Zasshi. 1996- 34(11): 1227−33.
- Harris J.A., Hyde D.M., Wang Q.J., Stovall M.Y., Giri S.N. Repeated episodes of C5a-induced neutrophil influx do not result in pulmonary fibrosis Inflammation. 1991- 15(3):233−50.
- Hartman ТЕ, Primack SL, Kang EY, et al. Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia: assessment with serial CT. Chest 1996- 110:378−82.
- Haslam PL, Poulter LW, Rossi GA, et al. The clinical role of BAL in idiopathic pulmonary fibrosis. Eur Respir J 1990- 3:940−2.
- Hayashi H., Ozaki Т., Nakamura Y., Kamei Т., Kawaji K., Tani K., Noda Y. C5 contents and neutrophil chemotactic activities in bronchiolar and alveolar regions. Nihon Kyobu Shikkan Gakkai Zasshi. 1991- 29(6):677−84.
- Hayashi S., Yoshida M., Sakuma-Mochizuki J. Effects of in vivo instillation of genes coding for cytokines on pulmonary fibrosis. Nihon Kyobu Shikkan Gakkai Zasshi. 1996- 34:190−4.
- Homolka J., Ziegenhagen M.W., Gaede K.I., Entzian P., Zissel G., Muller-Quernheim J. Systemic immune cell activation in a subgroup of patients with idiopathic pulmonary fibrosis. Respiration. 2003- 70(3):262−9.
- Honore I., Nunes H., Groussard O., Kambouchner M., Chambellan A. Acute respiratory failure after interferon-gamma therapy of end-stage pulmonary fibrosis. Am J. Respir. Crit. Care Med. 2003- 167(7):953−7.
- Huaux F, Liu T, McGarry B, Ullenbruch M, Phan SH. Dual roles of IL-4 in lung injury and fibrosis. J Immunol. 2003−170(4):2083−92.
- Hubbard R, Lewis S, Richards K, Johnston I, Britton J. Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis. Lancet 1996- 347:284−9.
- Hubbard R., Venn A., Lewis S., et al. Lung cancer and cryptogenic fibrosing alveolitis. A population-based cohort study //Am.J. Respir.Crit. Care Med.-2000.-Vol.161.-P. 5−8.
- Hunninghake G.W., Kalica A.R. Approaches to the treatment of pulmonary fibrosis. Am.J.Respir.Crit.Care Med. 1995- 151: 915−8.
- Ishii Y. Role of adhesion molecules in the pathogenesis of COPD. Nippon Rinsho 1999, V.57, N9, P.1965−1971.
- Iwai K.T., Mori N., Yamada M., Yamaguchi M., Hosoda Y. Idiopathic pulmonary fibrosis: epidemiologic approaches to occupational exposure. // Am. J. Respir. Crit. Care Med. 1994.- Vol.150. — P. 670−675.
- Jakubzick C., Choi E.S., Joshi B.H., Keane M.P., Kunkel S.L., Puri R.K., Hogaboam C.M. Therapeutic attenuation of pulmonary fibrosis via targeting of IL-4- and IL-13-responsive cells. J. Immunol. 2003- 171(5):2684−93.
- Johnston I.D., Prescott R.J., Chalmers J.C., et al. British Thoracic Society study of cryptogenic fibrosing alveolitis: current presentation and initial management. \ Thorax. -1997 Vol.52. — P 38−44.
- Jones H.A., Schofield J.B., Krausz Т., et al. Pulmonary fibrosis correlates with duration of tissue neutrophil activation. Am. J. Respir. Crit. Care Med., 1998, V.158, N2, P. 620−628.
- Kalra S., Utz J.P., Ryu J.H. Interferon gamma-lb therapy for advanced idiopathic pulmonary fibrosis. Mayo Clin. Proc. 2003- 78(9): 1082−7.
- Kasper M., Haroske G. Alterations in the alveolar epithelium after injury leading to pulmonary Alterations in the alveolar epithelium after injury leading to pulmonary. Histol. Histopathol. 1996- 11(2):463−83
- Kasper M., Koslowski R., Luther Т., Schuh D., Muller M., Wenzel K.W. Immunohistochemical evidence for loss of 1С AM-1 by alveolar epithelial cells in pulmonary fibrosis. Histochem. Cell. Biol. 1995- 104(5):397−405.
- Katzenstein A., Myers J. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. //Am.J. Respir.Crit. Care Med. -1998.-Vol.157.-P. 1301−1315.
- Katzensten AL, Myers JL, Mazur M. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986- 10:256−67.
- Keane M.P., Arenberg D.A., Lynch J.P. 3rd, Whyte R.I., Iannettoni M.D. The CXC chemokines, IL-8 and IP-10, regulate angiogenic activity in idiopathic pulmonary fibrosis. J. Immunol. 1997- 159(3): 1437−43.
- Kelley J. Cytokines of the lung. Am Rev Respir Dis. 1990- 141(3):765−88.
- Kelly M., Kolb M., Bonniaud P., Gauldie J. Re-evaluation of fibrogenic cytokines in lung fibrosis. Curr Pharm Des. 2003- 9(l):39−49.
- King ТЕ. Jr. Diagnostic advances in idiopathic pulmonary fibrosis. Chest 1991−100:238−41.
- Ко lb M., Margetts P. J., Anthony D.C., Pitossi F., Gauldie J. Transient expression of IL-lbeta induces acute lung injury and chronic repair leading to pulmonary fibrosis. J. Clin. Invest. 2001- 107(12): 1529−36.
- Kotecha S. Cytokines in chronic lung disease of prematurity. Eur J Pediatr. 1996- 155(2):S14−7.
- Kotecha S., Wilson L., Wangoo A., Silverman M., Shaw R.J. Increase in interleukin (IL)-l beta and IL-6 in bronchoalveolar lavage fluid obtained from infants with chronic lung disease of prematurity. Pediatr Res. 1996−40(2):250−6.
- Kunkel S.L., Lukacs N., Strieter R.M. Chemokines and their role in human disease. Agents Actions Suppl. 1995- 46:11−22.
- Kunkel S.L., Standiford Т., Kasahara K., Strieter R.M. Interleukin-8 (IL-8): the major neutrophil chemotactic factor in the lung. Exp.- Lung Res. 1991- 17(1): 17−23.
- Lasky J.A., Brody A.R. Interstitial fibrosis and growth factors. Environ Health Perspect. 2000- 108 Suppl 4:751−62.
- Lehnert B.E., Yaldez Y.E., Lehnert N.M., Park M.S., Englen M.D. Stimulation of rat and murine alveolar macrophage proliferation by lung fibroblasts. Am J Respir Cell Mol Biol. 1994- ll (4):375−85.
- Liebow A.A., Smith D.E. New concepts and entities in pulmonary disease. In: The Lung, hrsg. von A.A. Liebow. Williams & Wilkins. Baltimore, 1968
- Liebow A.A., Steer A., Billingsley J.G. Desqamative interstitisl pneumonia. //Am. J. Med. 1965. — Vol. 39.- P. 369
- Losa Garcia J.E., Rodriguez F.M., Martin de Cabo M.R. Evaluation of inflammatory cytokine secretion by human alveolar macrophages. Mediators Inflamm. 1999- 8(1):43−51.
- Lozano J., Hermosa M.J., Sanchez Martin M.M., Angel-Moreno A. Pulmonary fibrosis. The fibrogenic factors and therapeutic possibilities. An Med. Interna. 2000- 17(10):549−54.
- Lu C., Zhao H., Hou X. Studies on pulmonary fibrosis induced by interstitial macrophages. Zhonghua Jie He He Hu Xi Za Zhi. 1998- 21(ll):686−8.
- Lukacs N.W., Hogaboam C., Chensue S.W., Blease K., Kunkel S.L. Type 1/type 2 cytokine paradigm and the progression of pulmonary fibrosis. Chest. 2001- 120(1 Suppl):5S-8S.
- Lynch J.P. 3rd, Standiford T.J., Rolfe M.W., Kunkel S.L., Strieter R.M. Neutrophilic alveolitis in idiopathic pulmonary fibrosis. The role of interleukin-8. Am Rev. Respir. Dis. 1992- 145(6):1433−9.
- Lynch JP 3rd. White E. Flaherty K. Corticosteroids in idiopathic pulmonary fibrosis.//Current Opinion in Pulmonary Medicine. 2001 Sep.-Vol., 7(5) — P.298−308.
- Martinet Y., Menard O., Vaillant P., Vignaud J.M., Martinet N. Cytokines in human lung fibrosis. Arch. Toxicol. Suppl. 1996- 18:127−39.
- Moodley Y.P., Misso N.L., Scaffidi A.K., Fogel-Petrovic M. Inverse effects of interleukin-6 on apoptosis of fibroblasts from pulmonary fibrosis and normal lungs. Am J Respir Cell Mol Biol. 2003- 29(4):490−8.
- Moodley Y.P., Scaffidi A.K., Misso N.L., Keerthisingam C. Fibroblasts isolated from normal lungs and those with idiopathic pulmonary fibrosis differ in interleukin-6/gpl30-mediated cell signaling and proliferation. Am J Pathol. 2003- 163(l):345−54.
- Nagai S., Kitaichi M. Idiopathic Interstitial Pneumonias. In Bd.: Baum’s textbook Pulmonary Diseases. Sevent edition. Edited by J.D. Crapo et al., 2004.- P. 469−480.
- Nakao A., Hasegawa Y., Tsuchiya Y., Shimokata K. Expression of cell adhesion molecules in the lungs of patients with idiopathic pulmonary fibrosis. Chest. 1995- 108(l):233−9.
- Nathan S.D., Barnett S.D., Moran В., Helman D.L., Nicholson K., Ahmad S. Interferon gamma-lb as therapy for idiopathic pulmonary fibrosis. An intrapatient analysis. Respiration. 2004- 71(l):77−82.
- Paine R. 3rd, Ward P.A. Cell adhesion molecules and pulmonary fibrosis. Am J. Med. 1999- 107(3):268−79.
- Panos RJ. Therapy and managment of idiopathic pulmonary fibrosis. CompTher 1994−20:289−93.
- Pantelidis P., Southcott A.M., Black C.M., Du Bois R.M. Up-regulation of IL-8 secretion by alveolar macrophages from patients with fibrosing alveolitis: a subpopulation analysis. Clin. Exp. Immunol. 1997- 108(1):95−104.
- Papakonstantinou E., Aletras A.J., Roth M., Tamm M., Karakiulakis G. Hypoxia modulates the effects of transforming growth factor-beta isoforms on matrix-formation by primary human lung fibroblasts. Cytokine. 2003- 24(l-2):25−35.
- Pforte A. Diagnostic follow-up of alveolitis. Inflammatory activity can be determined by alveolar macrophages and their products. Fortschr. Med. 1995- 113(14):218.
- Phan S.H. New strategies for treatment of pulmonary fibrosis. Thorax 1995−50:415−21.
- Prasse A., Muller K.M., Kurz C., Hamm H., Virchow J.C. Jr. Does interferon-gamma improve pulmonary function in idiopathic pulmonary fibrosis? Eur. Respi. r J. 2003- 22(6):906-l 1.
- Raghu G. Interstitial lung disease: A diagnostic approach. Are CT scan and lung biopsy indicated in every patient? Am.J.Respir.Crit.Care Med. 1995- 151: 909−914.
- Regulation of the immune response by cytokines. By D. W. Mason. MRC Cellular Immunology Unit Sir W. Dunn Scyool of Pathology Oxford OXI 3REUK, 1995.
- Reynolds H.Y., Matthay R.A. Diffuse interstitial and alveolar inflammatory diseases. In: Chest Medicine. Essentials of pulmonary and critical care medicine. Ed. George R.B. Willams (Wilkins, Baltimore, Maryland), USA.
- Richeldi L. Interferon gamma-lb for pulmonary fibrosis. N Engl. J. Med. 2004- 350(17):1794−7.
- Riha R.L., Yang I.A., Rabnott G.C., Tunnicliffe A.M., Fong K.M., Zimmerman P.V. Cytokine gene polymorphisms in idiopathic pulmonary fibrosis. Intern Med J. 2004- 34(3): 126−9.
- Romagnani S. Thl/Th2 cells. Inflamm Bowel Dis. 1999- 5(4):285−94.
- Scadding J.G., Hinson K. Diffuse fibrosing alveolitis (diffuse interstitial fibrosis of the lungs): correlation of histology at biopsy with prognosis.// Thorax. 1967. — Vol.22. — P. 291−304.
- Selman M., Thannickal V.J., Pardo A., Zisman D.A., Martinez F.J., Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004- 64(4):405−30.
- Sempowski GD, Derdak S, Phipps RP. Interleukin-4 and interferon-gamma discordantly regulate collagen biosynthesis by functionally distinct lung fibroblast subsets. J Cell Physiol. 1996- 167(2):290−6.
- Shijubo N., Imai K., Aoki S., Hirasawa M., Sugawara H., Koba H., Tsujisaki M. Circulating intercellular adhesion molecule-1 (ICAM-1)antigen in sera of patients with idiopathic pulmonary fibrosis. Clin. Exp. Immunol. 1992-t89(1):58−62.
- Smith D.R., Kunkel S.L., Standiford T.J., Rolfe M.W., Lynch J.P. 3rd, Arenberg D.A. Increased interleukin-1 receptor antagonist in idiopathic pulmonary fibrosis. A compartmental analysis. Am J. Respir. Crit. Care Med. 1995-т151(6): 1965−73.
- Strieter R.M., Keane M.P. Cytokine Biology and the Pathogenesis of Interstitial Lung Disease.// New Approaches to Managing Idiopathic Pulmonary Fibrosis. 2000, Sept. — P. 27−35.
- Sueoka N., Sueoka E., Miyazaki Y., Okabe S., Kurosumi M., Takayama S., Fujiki H. Molecular pathogenesis of interstitial pneumonitis with TNF-alpha transgenicmice. Cytokine. 1998- 10(2):124−31.
- Suratt B.T., Lynch D.A., Cool C.D., Jones R.B., Brown K.K. Interferon-gamma for delayed pulmonary toxicity syndrome resistant to steroids. Bone Marrow Transplant. 2003- 31(10):939−41.
- Totani Y., Saitoh Y., Sakakibara H., Miyamori I., Ishizaki T. Clinical characterization of interleukin-8 in patients with idiopathic pulmonary fibrosis. Nihon Kokyuki Gakkai Zasshi. 2002- 40(11):869−74.
- Tsantes A., Tassiopoulos S., Papadhimitriou S.I., Bonovas S. Suboptimal erythropoietic response to hypoxemia in idiopathic pulmonary Chest. 2003- 124(2):548−53.
- Turner-Warwick M., Burrows В., Johnson A. Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax 1980- 35:171−80.
- Turner-Warwick M., Haslam P.L. The value of serial bronchalveolar lavages in assessing the clinical progress of patients with cryptogenic fibrosing alveoltis. Am Rev Respir Dis 1987- 135:26−34.
- Vaillant P., Menard O., Vignaud J.M., Martinet N., Martinet Y. The role of cytokines in human lung fibrosis. Monaldi Arch. Chest. Dis. 1996- 51(2): 145−52.
- Vergnon J.M., Vincent M., De The G., Mornex J.F., Weynants P., Brune J. Cryptogenic fibrosing alveolitis and Epstein-Barr virus: an association?// Lancet. 1984. — Vol. 2. — P. 768−771.
- Wallace W.A., Howie S.E. Immunoreactive interleukin 4 and interferon-gamma expression by type II alveolar epithelial cells in interstitial lung disease. J Pathol. 1999- 187(4):475−80.
- Wallace WA, Ramage EA, Lamb D, Howie SE. A type 2 (Th2-like) pattern of immune response predominates in the pulmonary interstitium of patients with ciyptogenic fibrosing alveolitis (CFA). Clin Exp Immunol. 1995- 101(3):436−41.
- Whyte M., Hubbard R., Meliconi R. Increased Risk of Fibrosing Alveolitis Associated with Interleukin-1 Receptor Antagonist and Tumor Necrosis Factor-alpha Gene Polymorphisms // Amer. J. Respir. Crit. Care Med. 2000. — V.162. — P. 755−758.
- Williams T.J., Jose P.J. Neutrophils in hronic obstructive pulmonary disease. Novartis Found. Symp. 2001, 234, Disk. 141−8, P. 136−141.
- Wynes M.W., Riches D.W. Induction of macrophage insulin-like growth factor-I expression by the Th2 cytokines IL-4 and IL-13. J. Immunol. 2003- 171(7):3550−9.
- Xaubet A., Agusti C., Luburich P. et al. Interleukin-8 expression in bronchoalveolar lavage cells in the evalution of alveolitis in idiopathis fibrosis. Respir. Med. 1998, V.92, N2, P.338−344.
- Yu Y.L., Yang G.Z. TSE- alpha mRNA expression in bronchoalveolar lavage cells from patients with lung fibrosis and TNF alpha activity in the lavage supernatants. Chin. Med. J. (Engl). 1993- 106(1): 13−6.
- Zhang K., Phan S.H. Cytokines and pulmonary fibrosis. Biol. Signals. 1996- 5(4):232−9.
- Zhang-Hoover J., Sutton A., van Rooijen N., Stein-Streilein J. A critical role for alveolar macrophages in elicitation of pulmonary immune fibrosis. Immunology. 2000- 101 (4):501−11.
- Zhao H., Lu С., Hou X., Yu R. In vitro studies on the bioactive materials released by lung fibroblasts in experimental pulmonary fibrosis. Zhonghua Jie He He Hu Xi Za Zhi. 1999- 22(l):54−6.
- Zhou Y., Hagood J.S., Murphy-Ullrich J.E. Thy-1 expression regulates the ability of rat lung fibroblasts to activate transforming growth factor-beta in response to fibrogenic stimuli. Am J. Pathol. 2004- 165(2):659−69.
- Ziegenhagen M.W., Zabel P., Zissel G., Schlaak M., Muller-Quernheim J. Serum level of interleukin 8 is elevated in idiopathic pulmonary fibrosis indicates disease activity. Am J. Respir. Crit. Care Med. 1998- 157 (3 Pt l):762−8.
- Ziesche R., Hofbauer E., Wittmann K., et al. A preliminary study of long-term treatment with interferon gamma-lb and low-dose prednisolone in patients wish idiopathic pulmonary fibrosis. W N. Engl. J. Med. 1999-Vol.-341.- P.1264−1269.